Flexible Lab Information Software

Start Modernizing Your Lab’s Workflow for as Low as $2,500

If your lab is looking to purchase and implement a laboratory information system (LIS), you’ve come to the right place. For over 40 years, Psychē Systems has continuously innovated and delivered a robust portfolio of specialty LIS that help medical laboratories of every type and size successfully optimize both efficiency and cost-effectiveness. Our comprehensive suite of hosted or installed LIS software solutions are highly regarded as the best in the industry.

Contact Capterra

Fill Out The Form Below

Product(s) for which you would like a demo

Psychē Systems’ advanced solutions include our best-of-breed LIS/MIMS applications.

Psychē Systems’ advanced solutions include our best-of-breed LIS applications including NucleoLIS® and WindoPath®. NucleoLIS supports molecular, cytogenetic, toxicology, and clinical lab testing. WindoPath is a fully CAP- and CLIA-compliant application that supports anatomic pathology and niche areas such as dermatopathology, gastroenterology, and urology.

In addition, we offer a full suite of robust connectivity solutions, including automatic ordering with ē.Outreach, comprehensive electronic medical record (EMR) integration, and interfacing to laboratory instruments and other third-party systems. All our solutions can be securely hosted on-premise or within our hosted services environment.

Our Products

Enterprise Level products

WindoPath® Ē.ssential

nucleoLIS is tailored to the unique workflows of PCR, immunology and FISH. It is also used for karyotyping, DNA sequencing, next gen sequencing, pharmacogenomics, toxicology, and other laboratory-defined tests.

nucleoLIS® Ē.finity

nucleoLIS is tailored to the unique workflows of PCR, immunology and FISH. It is also used for karyotyping, DNA sequencing, next gen sequencing, pharmacogenomics, toxicology, and other laboratory-defined tests.

Learn More

What Our Customers Are Saying

Read More

Our NGS report looks awesome. It is very complicated and complex based on a combination of being able to provide the genes expressed, clinical trials that are available for the patient to participate in, and recommended drugs the patient can use for treatment. It was a very smart design.

Mathews Plamkoodan Laboratory Director